Free Trial
NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

DiaMedica Therapeutics logo
$3.85 +0.20 (+5.48%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$3.84 0.00 (-0.13%)
As of 07/9/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

Key Stats

Today's Range
$3.65
$3.88
50-Day Range
$3.51
$4.27
52-Week Range
$2.98
$6.82
Volume
261,167 shs
Average Volume
101,327 shs
Market Capitalization
$165.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

DiaMedica Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

DMAC MarketRank™: 

DiaMedica Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 850th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about DiaMedica Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DiaMedica Therapeutics is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DiaMedica Therapeutics is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DiaMedica Therapeutics has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DiaMedica Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.09% of the float of DiaMedica Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently increased by 11.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    DiaMedica Therapeutics does not currently pay a dividend.

  • Dividend Growth

    DiaMedica Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.09% of the float of DiaMedica Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently increased by 11.82%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 7.30% of the stock of DiaMedica Therapeutics is held by insiders.

    • Percentage Held by Institutions

      Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

    • Read more about DiaMedica Therapeutics' insider trading history.
    Receive DMAC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    DMAC Stock News Headlines

    DiaMedica Therapeutics Inc. (DMAC) - Yahoo Finance
    DMAC DiaMedica Therapeutics Inc. - Seeking Alpha
    WARNING: A Digital Dollar Is Still In The Works
    A digital dollar could theoretically be used as a surveillance tool for banks, federal agencies, and the Federal Reserve.
    See More Headlines

    DMAC Stock Analysis - Frequently Asked Questions

    DiaMedica Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, DMAC stock has decreased by 29.1% and is now trading at $3.85.

    DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18).
    Read the conference call transcript
    .

    DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

    Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD).

    Company Calendar

    Last Earnings
    5/13/2025
    Today
    7/09/2025
    Next Earnings (Estimated)
    8/06/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:DMAC
    CIK
    1401040
    Fax
    N/A
    Employees
    20
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $10.00
    Low Price Target
    $6.00
    Potential Upside/Downside
    +107.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$24.44 million
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.95 per share
    Price / Book
    4.05

    Miscellaneous

    Free Float
    39,753,000
    Market Cap
    $165.10 million
    Optionable
    Optionable
    Beta
    1.17
    Beginner's Guide To Retirement Stocks Cover

    Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

    Get This Free Report

    This page (NASDAQ:DMAC) was last updated on 7/10/2025 by MarketBeat.com Staff
    From Our Partners